MegaGen
South Korean dental implant manufacturer and total oral healthcare company with a presence in over 100 countries, offering implant systems, digital dentistry solutions, and surgical equipment.
- CEO / Founder
- Dr. Kwang Bum Park (박광범)
- Team Size
- 501-1000
- Stage
- Growth Stage
- Total Funding
- $31.8M
- Latest Round
- Debt
- Key Investors
- Straumann (2014-2015, CB repaid 2017); HB Investment (2018, exited 2025)
Technology & Products
Key Products
AnyRidge Implant System; BLUEDIAMOND IMPLANT System; ARi (Anterior Atrophic Ridge) Implant; BD Cuff; R2GATE Digital Planning & Guided Surgery; R2STUDIO Virtual Patient Technology; FACEGIDE Digital Orthognathic Solution; MEGA ISQ; MEG TorQ; MEG Engine; Unit Chair (N2/N3); Plasma Active; Waterlase (via BIOLASE)
Technical position · AMPulse analysis
Proprietary AnyRidge implant design with biologically-inspired thread pattern enabling high initial stability across D1-D4 bone densities; BLUEDIAMOND system with advanced loading protocol; R2GATE digital guided surgery platform for one-day implant workflow; 109 registered patents; EU CE MDR six certifications; FDA clearances for multiple systems.
Differentiation
Value Proposition
Doctor-designed dental implant systems with biologically-inspired designs (AnyRidge, BLUEDIAMOND) enabling accelerated loading, minimally invasive procedures, and predictable outcomes across all bone densities.
How They Differentiate
Founded and led by practicing dentists with deep clinical insight; proprietary biologically-inspired implant designs (AnyRidge with unique thread design for all bone densities); BLUEDIAMOND premium system addressing mechanical/biological complications; integrated digital ecosystem (R2GATE); strong global distribution in 100+ countries with 12 overseas subsidiaries.
Market & Competition
Target Customers
Dental clinicians, implant surgeons, dental clinics, and dental laboratories worldwide
Industry Verticals
Dental implantology; Digital dentistry; Oral surgery; Orthognathic surgery; Dental prosthetics
Competitors
Osstem Implant; Dentium; Neobiotech; DIO Implant
Growth & Milestones
Growth Metrics
2024 Revenue: KRW 304.8B (~$232M); 2024 Operating Profit: KRW 28.7B; 2024 Net Income: KRW 30.3B; Employees: 763 (2026); 70% of revenue from exports; 100+ countries; 12 overseas subsidiaries
Major Milestones
2002: Founded; 2004: First FDA clearance; 2006: Rescue 5mm short implant launched; 2009: AnyRidge system launched; 2011: $10M export tower; 2012: R2GATE digital guide system announced; 2014-2015: $30M CB investment from Straumann; 2017: Repaid Straumann CB, regained full independence; 2020: $70M export tower; 2024: Revenue surpassed KRW 300B ($304.8B); 2025: Acquired BIOLASE for $20.05M; 2026: IPO preparation with NH Investment & Securities, CFO hired
Recent coverage of MegaGen
AM patents
AM-relevant patents linked to this company.
- Patents
- 4
- Granted
- 3
- Families
- 4
Leading domains: application (4), process (3), equipment (1)
Filings by year: 2019: 1 · 2014: 1 · 2012: 1 · 2008: 1
- 입체형상의 골 이식재 및 그 제조방법1020160049046 · KR
- Implant image creating method and implant image creating system104955399 · CN
- 입체물 성형 시스템 및 그 방법1016636220000 · KR
- 골조직 광열치료용 이중층 구조의 복합 멤브레인 및 그 제조방법1022362120000 · KR